YuanDong Biopharmaceutical: Wholly-owned subsidiary's Ponatinib Tablets obtain drug registration certificate.

YuanDong Biotech announced that its wholly-owned subsidiary, Chengdu Shuode Pharmaceutical Co., Ltd., recently received the "Drug Registration Certificate" for Ponatinib Tablets approved and issued by the National Medical Products Administration. This drug is a third-generation BCR-ABL tyrosine kinase inhibitor for leukemia, and is the first generic drug in China approved under Category 4 chemical drugs, deemed to have passed consistency evaluation, with a specification of 15mg. The marketing authorization holder and manufacturing enterprise are both Chengdu Shuode Pharmaceutical Co., Ltd. The approval of this drug will not have a significant impact on the company's recent performance.